We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's Behind Ingevity's 27% Rally in the Past 6 Months?
Read MoreHide Full Article
Key Takeaways
Ingevity stock rose 26.6% in six months, beating the specialty chemicals industry and outpacing the S&P 500.
NGVT benefits from pine chemicals and caprolactone acquisitions that cut costs and expand margins.
NGVT drives growth via Performance Chemicals repositioning, European biofuels sales and capacity additions.
Ingevity Corporation (NGVT - Free Report) shares have gained 26.6% over the past six months. The company has also outperformed the Zacks Chemical - Specialty industry’s 7.3% decline and the S&P 500’s 11.8% increase over the same period.
Image Source: Zacks Investment Research
Ingevity Boosts Portfolio With Strategic Acquisitions
Ingevity is strengthening its portfolio through its focus on value-creating acquisitions that enhance efficiency and lend exposure to profitable markets. The acquisition of Georgia-Pacific’s pine chemicals business has delivered benefits through optimization of production, lower procurement and logistics costs, and margin expansion. The Capa caprolactone acquisition added a differentiated technology platform that has meaningful end-use applications such as coatings, adhesives and specialty polymers, resulting in a sustainable revenue stream. The Ozark Materials acquisition strengthens Ingevity’s presence in the construction market, which will help the company benefit from demand in the infrastructure market.
Long-Term Growth Initiatives Favor Ingevity
Beyond acquisitions, Ingevity is advancing initiatives to ensure long-term growth amid favorable trends in the end-markets. The company has successfully repositioned its Performance Chemicals business by exiting lower-margin markets, driving improved working capital, strong free cash flow and higher EBITDA.
The potential divestiture of Advanced Polymer Technologies will also help the company toward higher margins. Growth is further supported by first commercial Tall Oil Fatty Acid sales in European biofuels and expanded soy-based fatty acid production capacity. Capacity additions in caprolactone monomers and polyols, opportunities in the methane value chain and the globalization of the Pavement Technology business will enable growth.
Ingevity Corporation Price, Consensus and EPS Surprise
Some better-ranked stocks in the Basic Materials space are Agnico Eagle Mines (AEM - Free Report) , Kinross Gold Corporation (KGC - Free Report) and Harmony Gold Mining Company Limited (HMY - Free Report) .
The Zacks Consensus Estimate for AEM’s 2025 earnings is pegged at $7.87 per share, indicating a rise of 86.05%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 11.63%. AEM’s shares have gained 109.1% over the past year.
The Zacks Consensus Estimate for KGC’s 2025 fiscal-year earnings is pinned at $1.68 per share, indicating a 147.06% year-over-year increase. Its shares have surged 187.9% over the past year.
The Zacks Consensus Estimate for HMY’s current fiscal-year earnings is pinned at $2.68 per share, indicating a 111.02% year-over-year increase.HMY’s shares have gained 138.7% over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
What's Behind Ingevity's 27% Rally in the Past 6 Months?
Key Takeaways
Ingevity Corporation (NGVT - Free Report) shares have gained 26.6% over the past six months. The company has also outperformed the Zacks Chemical - Specialty industry’s 7.3% decline and the S&P 500’s 11.8% increase over the same period.
Image Source: Zacks Investment Research
Ingevity Boosts Portfolio With Strategic Acquisitions
Ingevity is strengthening its portfolio through its focus on value-creating acquisitions that enhance efficiency and lend exposure to profitable markets. The acquisition of Georgia-Pacific’s pine chemicals business has delivered benefits through optimization of production, lower procurement and logistics costs, and margin expansion. The Capa caprolactone acquisition added a differentiated technology platform that has meaningful end-use applications such as coatings, adhesives and specialty polymers, resulting in a sustainable revenue stream. The Ozark Materials acquisition strengthens Ingevity’s presence in the construction market, which will help the company benefit from demand in the infrastructure market.
Long-Term Growth Initiatives Favor Ingevity
Beyond acquisitions, Ingevity is advancing initiatives to ensure long-term growth amid favorable trends in the end-markets. The company has successfully repositioned its Performance Chemicals business by exiting lower-margin markets, driving improved working capital, strong free cash flow and higher EBITDA.
The potential divestiture of Advanced Polymer Technologies will also help the company toward higher margins. Growth is further supported by first commercial Tall Oil Fatty Acid sales in European biofuels and expanded soy-based fatty acid production capacity. Capacity additions in caprolactone monomers and polyols, opportunities in the methane value chain and the globalization of the Pavement Technology business will enable growth.
Ingevity Corporation Price, Consensus and EPS Surprise
Ingevity Corporation price-consensus-eps-surprise-chart | Ingevity Corporation Quote
NGVT’s Zacks Rank & Key Picks
NGVT currently sports a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Agnico Eagle Mines (AEM - Free Report) , Kinross Gold Corporation (KGC - Free Report) and Harmony Gold Mining Company Limited (HMY - Free Report) .
At present, AEM and KGF sport a Zacks Rank #1 (Strong Buy) each, while HMY carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for AEM’s 2025 earnings is pegged at $7.87 per share, indicating a rise of 86.05%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 11.63%. AEM’s shares have gained 109.1% over the past year.
The Zacks Consensus Estimate for KGC’s 2025 fiscal-year earnings is pinned at $1.68 per share, indicating a 147.06% year-over-year increase. Its shares have surged 187.9% over the past year.
The Zacks Consensus Estimate for HMY’s current fiscal-year earnings is pinned at $2.68 per share, indicating a 111.02% year-over-year increase.HMY’s shares have gained 138.7% over the past year.